Natural compound chaetocin induced DNA damage and apoptosis through reactive oxygen species‐dependent pathways in A549 lung cancer cells and in vitro evaluations by Qi Zhang, Feng Ruan, Maonan Yang, Qinghui Wen

“…Abstract There is an urgent need for potential pharmaceutics for lung cancer treatment due to the increased number of lung cancer deaths and the resistance of cancer cells to present therapeutics. …”
Get full text

Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysisResearch in context by Jiacheng Yao, Sihan Li, Lu Bai, Jun Chen, Chengbo Ren, Tingting Liu, Jingping Qiu, Jun Dang

Subjects: Get full text

Burdens of Tracheal, Bronchus, and Lung Cancer From 1990 to 2021 in China Compared to the Global Projection of 2036: Findings From the 2021 Global Burden of Disease Study by Yuxing Chen, Qingpeng Zeng, Muyu Li, Jiahui Jin, Jun Zhao

“…ABSTRACT Background Tracheal, bronchial, and lung cancers (TBL cancers) pose a significant global health challenge, with rising incidence and mortality rates, particularly in China. …”
Get full text

Neoadjuvant adebrelimab combined with chemotherapy (cisplatin/carboplatin and etoposide) for limited-stage small-cell lung cancer: a study protocol of phase 2 trial (NIUS) by Yan Zhang, Qian Huang, Mengxia Li, Xi Zheng, Yanyang Liu, Long Tian, Guizhi Chen, Hongyu Xu, Daxing Zhu

“…Introduction Small-cell lung cancer (SCLC) is a highly malignant neuroendocrine tumour, and concurrent chemoradiotherapy is the current recommended treatment for limited-stage SCLC. …”
Get full text

Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China by Jingyi Meng, Feifei Yan, Maochun Chen, Yuchen Ding, Zhe Feng, Wenzhang Lu, Jinsong Geng

“…Our study aimed to investigate preferences for public health insurance coverage of new anticancer drugs among non-small cell lung cancer (NSCLC) patients in China. Methods We identified six attributes of new anticancer drugs and adopted a Bayesian-efficient design to generate choice scenarios for a discrete choice experiment (DCE). …”
Get full text

Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer by Lulu Zhang, Lulu Zhang, Xiyuan Guo, Xiyuan Guo, Xiaoke Sun, Jue Liao, Qin Liu, Yingchun Ye, Zhihui Yang, Ratchada Cressey, Qing He, Qing Yuan, Qing Yuan

Subjects: Get full text

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial by Jeffrey M. Clarke, George R. Simon, Hirva Mamdani, Lin Gu, James E. Herndon, Thomas E. Stinchcombe, Neal Ready, Jeffrey Crawford, Guru Sonpavde, Stephen Balevic, Andrew B. Nixon, Michael Campa, Elizabeth B. Gottlin, Huihua Li, Ruchi Saxena, You Wen He, Scott Antonia, Edward F. Patz

“…We conducted a first-in-human phase 1b study dose escalation trial of GT103 in refractory non-small cell lung cancer to assess the safety of GT103 (NCT04314089). …”
Get full text

Partial Stereotactic Ablative Radiotherapy Boost Before Conventional Radiotherapy (P‐SABR) for Large (> 5 cm) Unresectable Stage III Nonsmall Cell Lung Cancer by Yun Bai, Xianshu Gao, Shangbin Qin, Shanshi Li, Mingwei Ma, Xi Cao, Feng Lyu, Jiayan Chen, Xin Qi, Siwei Liu, Yan Gao, Hongzhen Li, Xiaomei Li, Xiaoying Li, Xueying Ren, Lei Huang

“…This study aims to evaluate the efficacy and safety of partial SABR boost before conventional radiotherapy (P‐SABR) for the treatment of large (> 5 cm) unresectable stage III nonsmall cell lung cancer (NSCLC). Methods From April 2014 to January 2024, 44 patients with > 5 cm unresectable T3‐4N0‐3M0 stage III NSCLC were analyzed. …”
Get full text

Thermal ablation included in multimodality treatment predicts enhanced survival in advanced non-small cell lung cancer: a propensity score-matched outcome study by Stella Chin-Shaw Tsai, Yi-Min Chen, Yueh-Han Ku, Chia-Hsuan Hsu, Tzu-Hsuan Hsiao, Pin-Hsu Liao, Tzu-Chin Wu, Frank Cheau-Feng Lin

Subjects: Get full text

Diagnostic accuracy of MRI-based radiomic features for EGFR mutation status in non-small cell lung cancer patients with brain metastases: a meta-analysis by Yuqin Long, Rong Zhao, Xianfeng Du

Subjects: Get full text

Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway by Lile Wang, Lu Xu, Shuhua Han, Xiaoli Zhu

“…Anlotinib is an effective targeted therapy for advanced non-small-cell lung cancer (NSCLC) and has been found to mediate chemoresistance in many cancers. …”
Get full text

γ-H2AX: A Novel Prognostic Marker in a Prognosis Prediction Model of Patients with Early Operable Non-Small Cell Lung Cancer by E. Chatzimichail, D. Matthaios, D. Bouros, P. Karakitsos, K. Romanidis, S. Kakolyris, G. Papashinopoulos, A. Rigas

“…The aim of the current study was to assess the prognostic value of a series of clinical and molecular variables with the addition of γ-H2AX—a new DNA damage response marker—for the prediction of prognosis in patients with early operable non-small cell lung cancer by comparing the γ-H2AX-based artificial network prediction model with the corresponding LR one. …”
Get full text

Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study by Egbert F Smit, Willemijn S M E Theelen, Michiel M Smeenk, Vincent van der Noort, Jeroen M A Hendrikx, Hanieh Abedian Kalkhoran

“…However, clinical efficacy data are lacking.Methods In this retrospective cohort trial, consecutive patients with advanced non-small cell lung cancer (NSCLC) who received ≥1 cycle pembrolizumab±chemotherapy at two tertiary institutions were included. …”
Get full text

Survival outcomes of surgery and adjuvant chemotherapy in early-stage small cell and large cell lung cancer: a novel focus on tumors less than 1 cm by Jorge Raul Vazquez-Urrutia, Junjia Zhu, Shinkichi Takamori, Max Greenberg, Priyanka Bhatia, Takefumi Komiya

Subjects: “…Lung cancer…”
Get full text

Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials by Andrea Messori, Andrea Ossato, Lorenzo Gasperoni, Luna Del Bono, Alessandro Inno, Vera Damuzzo

Subjects: Get full text

Rhopalurus junceus scorpion venom induces G2/M cell cycle arrest and apoptotic cell death in human non-small lung cancer cell lines by Alexis Díaz-García, Ángel Garrido, Jenny Laura Ruiz-Fuentes, Tamara Hermosilla, Diego Varela

“…Abstract Background: Non-small cell lung cancers (NSCLC) represent the primary cause of cancer-related deaths worldwide. …”
Get full text

Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis by Mingfeng He, Xue Wu, Li Li, Guangming Yi, Yitian Wang, Hengqiu He, Ying Ye, Ruiqin Zhou, Zaicheng Xu, Zhenzhou Yang

Subjects: “…Non-small-cell lung cancer…”
Get full text

Global, regional and national burden of tracheal, bronchus, and lung cancer attributable to ambient particulate matter pollution from 1990 to 2021: an analysis of the global burden of disease study by Jianguo Lu, Xiangmei Zhao, Shaoyin Gan

Get full text

A qualitative study on dietary distress of lung cancer patients during chemotherapy (肺癌患者化疗期间饮食困扰的质性研究) by ZHANG Yueyu (张月瑜), YIN Yuanyuan (尹媛媛)

Subjects: “…lung cancer…”
Get full text

Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. by Richard Junior Zapata Dongo, Diletta Fontana, Luca Mologni, Juan Enrique Faya Castillo, Stefany Fiorella Infante Varillas

“…The anaplastic lymphoma kinase (ALK) oncoprotein plays a crucial role in non-small cell lung cancer (NSCLC) by activating signaling pathways involved in cell proliferation and survival through constitutive phosphorylation. …”
Get full text